Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer
Open Access
- 6 June 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (11), 4068
- https://doi.org/10.3390/ijms21114068
Abstract
Breast cancer (BC) is a heterogeneous disease characterized by different biopathological features, differential response to therapy and substantial variability in long-term-survival. BC heterogeneity recapitulates genetic and epigenetic alterations affecting transformed cell behavior. The estrogen receptor alpha positive (ERα+) is the most common BC subtype, generally associated with a better prognosis and improved long-term survival, when compared to ERα-tumors. This is mainly due to the efficacy of endocrine therapy, that interfering with estrogen biosynthesis and actions blocks ER-mediated cell proliferation and tumor spread. Acquired resistance to endocrine therapy, however, represents a great challenge in the clinical management of ERα+ BC, causing tumor growth and recurrence irrespective of estrogen blockade. Improving overall survival in such cases requires new and effective anticancer drugs, allowing adjuvant treatments able to overcome resistance to first-line endocrine therapy. To date, several studies focus on the application of loss-of-function genome-wide screenings to identify key (hub) “fitness” genes essential for BC progression and representing candidate drug targets to overcome lack of response, or acquired resistance, to current therapies. Here, we review the biological significance of essential genes and relative functional pathways affected in ERα+ BC, most of which are strictly interconnected with each other and represent potential effective targets for novel molecular therapies.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG-23068)
This publication has 113 references indexed in Scilit:
- Potent inhibition of DOT1L as treatment of MLL-fusion leukemiaBlood, 2013
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory FactorCell Reports, 2013
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- RNA-guided genetic silencing systems in bacteria and archaeaNature, 2012
- Epigenetic Regulation in Estrogen Receptor Positive Breast Cancer—Role in Treatment ResponseJournal of Mammary Gland Biology and Neoplasia, 2010
- Estrogen Receptor Alpha Represses Transcription of Early Target Genes via p300 and CtBP1Molecular and Cellular Biology, 2009
- The DEAD box RNA helicases p68 (Ddx5) and p72 (Ddx17): novel transcriptional co-regulatorsBiochemical Society Transactions, 2008
- A probability-based approach for the analysis of large-scale RNAi screensNature Methods, 2007
- Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1Cell, 2005